SCHEMBL468878

SCHEMBL468878

CC(=O)N[C@@H](CCc1c[nH]c2ccccc12)C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.61
KMT2A Q03164 2/20 0.60
MEN1 O00255 1/20 0.60
LMNA P02545 1/20 0.60
CYP1A2 P05177 1/20 0.60
PKM P14618 1/20 0.60
TSHR P16473 1/20 0.60
CYP2C19 P33261 1/20 0.60
BLM P54132 1/20 0.60
TACR1 P25103 3/20 0.57
ACE P12821 3/20 0.57
ITGB2 P05107 1/20 0.55
ICAM1 P05362 1/20 0.55
ITGAL P20701 1/20 0.55
KDM4E B2RXH2 2/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
APAF1 O14727 1/20 0.54
POLB P06746 1/20 0.54
MAPT P10636 1/20 0.54
RECQL P46063 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22769512 1.00 ALOX15 (0.61) ALOX15KMT2AMEN1LMNACYP1A2
Acetyltryptophan SCHEMBL4216452 0.87 ALOX15 (0.79) ALOX15TACR1ACEITGB2ICAM1
Acetyltryptophan SCHEMBL57141 0.87 ALOX15 (0.79) ALOX15TACR1ACEITGB2ICAM1
Acetyltryptophan SCHEMBL29401158 0.87 ALOX15 (0.79) ALOX15TACR1ACEITGB2ICAM1
Acetyltryptophan SCHEMBL57140 0.87 ALOX15 (0.79) ALOX15TACR1ACEITGB2ICAM1
Acetyltryptophan SCHEMBL702442 0.87 ALOX15 (0.79) ALOX15TACR1ACEITGB2ICAM1
Acetyltryptophan SCHEMBL4216450 0.87 ALOX15 (0.79) ALOX15TACR1ACEITGB2ICAM1
Acetyltryptophan SCHEMBL29360698 0.87 ALOX15 (0.79) ALOX15TACR1ACEITGB2ICAM1
Acetyltryptophan SCHEMBL23933298 0.86 ALOX15 (0.77) ALOX15TACR1ACEITGB2ICAM1
Acetyltryptophan SCHEMBL11471934 0.86 ALOX15 (0.77) ALOX15TACR1ACEITGB2ICAM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3039068-B1 MOISTURE CURABLE COMPOUND WITH AMINO ACIDS MOMENTIVE PERFORMANCE MAT INC (US) 2020-12-16 EP claimed
US-9914809-B2 Moisture curable composition with amino acids MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2018-03-13 US claimed
US-20160200880-A1 MOISTURE CURABLE COMPOSITION WITH AMINO ACIDS MOMENTIVE PERFORMANCE MATERIALS INC. 2016-07-14 US claimed
EP-3039068-A1 MOISTURE CURABLE COMPOUND WITH AMINO ACIDS Momentive Performance Materials Inc. (US) 2016-07-06 EP claimed
WO-2015031712-A1 MOISTURE CURABLE COMPOUND WITH AMINO ACIDS MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2015-03-05 WO claimed
US-RE44302-E1 N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use YU RUEY J (US) 2013-06-18 US claimed
US-RE44017-E1 N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use YU RUEY J (US) 2013-02-19 US claimed
US-RE42902-E1 N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use TRISTRATA, INC. (US) 2011-11-08 US claimed
US-RE41339-E1 N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use TRISTRATA, INC. (US) 2010-05-18 US claimed
US-RE41278-E1 N-acetyl aldosamines and related N-acetyl compounds, and their topical use TRISTRATA, INC. 2010-04-27 US claimed
EP-2080504-A2 Topical composition comprising n-acetylaldosamines or n-acetylamino acids Yu, Ruey J. (US) 2009-07-22 EP claimed
EP-1639994-A2 Topical composition comprising N-acetylaldosamines or N-acetylamino acids Yu, Ruey J., Dr. (US) 2006-03-29 EP claimed
EP-1570840-A2 TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS Yu, Ruey J., Dr. (US) 2005-09-07 EP claimed
US-6524593-B1 Alleviate or improve various cosmetic conditions and dermatological disorders, skin, hair, nails TRISTRATA, INC. 2003-02-25 US claimed
EP-1143925-A1 TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS Yu, Ruey J., Dr. (US) 2001-10-17 EP claimed
US-6159485-A COSMETICS; SKIN DISORDERS YUGENIC LIMITED PARTNERSHIP (US) 2000-12-12 US claimed
WO-2000040217-B1 TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS YUGENIC LIMITED PARTNERSHIP (US) 2000-10-05 WO claimed
WO-2000040217-A1 TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS YUGENIC LIMITED PARTNERSHIP (US) 2000-07-13 WO claimed
US-20230109142-A1 CORONA VIRUS VACCINE IMMUNOR AS (NO) 2023-04-06 US disclosed
WO-2000012542-A2 CYTOTOXIC LACTOFERRIN DERIVATIVES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES ALPHARMA AS (NO) 2000-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230109142-A1 CORONA VIRUS VACCINE CALCA, HCFC1, STING1 ALOX15 1478/4885KMT2A 1645/4885MEN1 3247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.